Clinical trial · Observational
Mechanism and Outcome of Acute Ischemic Stroke in Cancer Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Stroke is a part of circulatory diseases which are the primary cause of death in Egypt. It accounts 14% of all deaths thus ranks the 2nd after ischemic heart disease. Cancer accounts 9% of population mortality in Egypt. Nearly 108,600 Egyptians newly diagnosed with cancer each year. The interrelationship between stroke and cancer is complex. Cancer may directly or indirectly lead to stroke via: hypercoagulability, nonbacterial thrombotic endocarditis (NBTE), direct tumor compression of blood vessels or treatment-related effects which potentiate stroke. The risk of ischemic stroke after chemotherapy is largely increased by the use of certain types of chemotherapy not only by cancer histologic type. Brain infarction usually a subsequent complication appears sometimes shortly after chemotherapy. Chronic radiation vasculopathy that affects medium and large intra- and extra-cranial arteries is characterized by increasing rates of hemodynamic significant stenosis with time after radiotherapy. The study aims to clarify the relation between cancer and its treatment with ischemic stroke by discussing the different mechanisms by which a vascular insult happen causing neurological deficit. The study provides more information about cancer patients with higher risk to develop ischemic stroke more than other patients by identifying co morbidities and dosage of cancer treatment that causes cerebrovascular insults.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Ischemic Stroke | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Risk factors | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Cancer patients with acute ischemic stroke
- description
- Eighty patients previously or currently suffering from manifest cancer on or not on cancer treatment who developed stroke
- interventionNames
- Other: Risk factors
- label
- Control patients with acute ischemic stroke without cancer
- description
- Eighty patients with acute ischemic stroke without cancer
- interventionNames
- Other: Risk factors
Primary outcomes (1)
- measure
- Modified Rankin Scale
- timeFrame
- 6 months
- description
- The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It has become the most widely used clinical outcome measure for stroke clinical trials.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 25 Years
- Maximum age
- 89 Years
Show eligibility criteria text
Inclusion Criteria: * 80 patients previously or currently suffering from manifest cancer on or not on cancer treatment who developed stroke * 80 control patient with ischemic storke without cancer Exclusion Criteria: * Patients developed cerebrovascular insults prior to the onset of cancer * Cancer patients with symptoms mimic stroke. * Cancer patients with focal neurological deficit due to direct effect of malignant tumor. * Patients missed their follow up. * Patients with traditional cerebrovascular risk factors such as (hypertension, hyperlipidemia, diabetes and atrial fibrillation) prior to cancer diagnosis.
References
Publications (0)
Data not yet available